MedTrace Logo

Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women

NCT00786409 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2018-02-15

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the immunogenicity and safety of the HPV vaccine Gardasil in young women.

Conditions

Interventions

BIOLOGICAL

Gardasil

0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.

Sponsors & Collaborators

Principal Investigators

  • Linda Wagner-Weiner, MD · University of Chicago

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
26 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2010-08-31
Completion
2011-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00786409 on ClinicalTrials.gov